# A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy

> **NCT04352413** · PHASE2 · TERMINATED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 45 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** PLM60

## Key facts

- **NCT ID:** NCT04352413
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-18
- **Primary completion:** 2022-01-30
- **Final completion:** 2022-04-29
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** The sponsor has adjusted its R\&D strategy.
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04352413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04352413, "A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04352413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*